Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 8,685 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Longitudinal Studies Clear all

Conditions: Chimerism, Blood Transfusion, Wounds and Injuries
Interventions: Not listed
Lead sponsor: Vitalant Research Institute; Other
Eligibility: 12 Years and older
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: Vyvanse (lisdexamfetamine dimesylate); Drug
Lead sponsor: Shire; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 46
States / cities: Scottsdale, Arizona • El Centro, California • Rolling Hills Estates, California + 42 more

Conditions: Autism Spectrum Disorder, Autism, Developmental Delay, Autism, Early Infantile, Autism, Infantile
Interventions: Assessment by Expert Clinician During Behavioral Intervention (ABA or similar), Assessment by the EarliPoint Assessment For Autism Spectrum Disorder; Behavioral · Device
Lead sponsor: EarliTec Diagnostics, Inc; Industry
Eligibility: 15 Months to 84 Months
Enrollment: 325 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 9
States / cities: Phoenix, Arizona • Glendale, California • San Rafael, California + 6 more

Conditions: Multiple Sclerosis
Interventions: MRI; Other
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Congenital Hearing Loss Secondary to Biallelic Mutations in the Otoferlin Gene (OTOF), Biallelic Mutations in the Gap Junction Beta 2 (GJB2) Gene, Digenic Mutations in GJB2/Gap Junction Beta 6 (GJB6) Genes
Interventions: Not listed
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: Up to 7 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Phoenix, Arizona • Columbus, Ohio

Conditions: Autoimmune Liver Disease, Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Interventions: Not listed
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years to 23 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2031
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Occlusive Stroke
Interventions: Asahi Chikai Black 18 neurovascular guidewire; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Schizophrenia, Psychotic Disorders
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 12 Years to 35 Years
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 2
States / cities: New Haven, Connecticut • Chapel Hill, North Carolina

Conditions: Inguinal Hernia
Interventions: Not listed
Lead sponsor: United States Naval Medical Center, Portsmouth; Federal
Eligibility: 21 Years and older · Male only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Portsmouth, Virginia

Conditions: BRCA1 Gene Mutation, BRCA2 Gene Mutation
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 35 Years to 50 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Fatty Liver
Interventions: Mod Fat/Low Processed Carb Diet and Moderate Exercise, Low Fat Diet and Moderate Exercise, Moderate Exercise Only; Behavioral
Lead sponsor: San Antonio Military Medical Center; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Pain, Postoperative, Otitis Media
Interventions: Ketorolac, Fentanyl; Drug
Lead sponsor: Anica Crnkovic; Other
Eligibility: 8 Months to 7 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Albany, New York

Conditions: Indolent Non-Hodgkin's Lymphoma
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma
Interventions: Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI, Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hemorrhoids, Internal
Interventions: HET Bipolar System; Device
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: SARS-CoV-2, Influenza A, Influenza B, COVID-19
Interventions: LumiraDx SARS-CoV-2 Ag Ultra, LumiraDx SARS-CoV-2 & Flu A/B; Diagnostic Test
Lead sponsor: LumiraDx UK Limited; Industry
Eligibility: Not listed
Enrollment: 716 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 10
States / cities: Garden Grove, California • Lomita, California • DeLand, Florida + 6 more

Conditions: Heart Transplant, Heart Failure, Transplant; Failure, Heart
Interventions: Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Assist Transport (XHAT); Device
Lead sponsor: XVIVO Perfusion; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 14
States / cities: La Jolla, California • Los Angeles, California • Stanford, California + 9 more

Conditions: Gastrointestinal Complication
Interventions: PrevisEA device; Device
Lead sponsor: Entac Medical Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Orlando, Florida • Chicago, Illinois • Grand Rapids, Michigan + 5 more

Conditions: Actinic Keratoses
Interventions: Cryotherapy, 5Fluorouracil; Procedure · Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Crohn's Disease
Interventions: Adacolumn, Sham; Device
Lead sponsor: Otsuka America Pharmaceutical; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 28
States / cities: Phoenix, Arizona • Roseville, California • San Francisco, California + 24 more

Conditions: Respiratory Failure
Interventions: Etomidate (20mg) or Midazolam (7mg); Drug
Lead sponsor: St. Luke's Hospital, Pennsylvania; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Bethlehem, Pennsylvania

Conditions: To Collect Information About Visual Outcomes and Participant Satisfaction
Interventions: Tecnis one-piece MF IOL, Crystalens AO; Device
Lead sponsor: Innovative Medical; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Lake Villa, Illinois

Conditions: Postdural Puncture Headache
Interventions: Sphenopalatine Ganglion Block, Placebo; Procedure
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Mycosis Fungoides and Sézary Syndrome
Interventions: Poteligeo; Drug
Lead sponsor: Kyowa Kirin Pharmaceutical Development Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 5
States / cities: Baltimore, Maryland • St Louis, Missouri • New York, New York + 2 more

Search by objective public record fields.

Transfusion-Associated Microchimerism in Individuals Receiving a Blood Transfusion After a Traumatic Injury

Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD

Treatment Monitoring in Autism Spectrum Disorder (ASD) in Children

A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months

A Natural History Study in Pediatric Participants With Hearing Loss Due to OTOF, GJB2, or GJB2/GJB6 Mutations

MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease

SURE 18 Registry -Asahi Chikai Black 18 in LVO Stroke

Enhancing the Prospective Prediction of Psychosis

The Economic Impact of Four Varieties of Mesh Inguinal Hernia Repair- a Double-Blinded, Prospective, Randomized Trial

Prospective Research of Outcomes After Salpingo-oophorectomy

Evaluation of Diet and Exercise in Patients With Non-Alcoholic Fatty Liver Disease

Ketorolac Sublingual vs. Fentanyl Intranasal in Pain Control for Bilateral Myringotomy and Tubes (BMT) Placement in Children

Prospective Study of Possible Infectious Disease - Associated Antigen Drive in Previously Untreated Indolent Lymphoma

VENTURI (VENTilation Using Respiratory Imaging)

Safety and Efficacy Study of HET Bipolar System for Treatment of Stage I and Stage II Hemorrhoids

POC Performance Evaluation of LumiraDx SARS-CoV-2 Ag Ultra and SARS-CoV-2 & Flu A/B Tests.

XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)

Evaluation of the PrevisEA Device for Predicting Gastrointestinal Impairment

Efficacy and Safety of Cryotherapy Versus 5-Fluorouracil in the Treatment of Actinic Keratosis

Study for the Treatment of Crohn's Disease With Adacolumn

Effectiveness and Safety Study of Etomidate Versus Midazolam to Help Place a Breathing Tube Outside of the Hospital.

Prospective Evaluation of Visual Outcomes With Tecnis One-Piece Multifocal Intraocular Lenses Compared With Patients Previously Implanted With Crystalens Aspheric Optic (AO)

Sphenopalatine Ganglion Block for Postdural Puncture Headache in the Emergency Department

Real World Observational Study of Poteligeo in Adult Patients With MF and SS (PROSPER)